In a research report released Friday, Rodman & Renshaw analyst Amit Dayal reiterated a Buy rating on shares of Second Sight Medical Products Inc (NASDAQ:EYES), …
On the eve of FDA advisory committee for brodalumab, a new biologic drug being developed for psoriasis, analyst Raghuram Selvaraju of Rodman & …
Rodman & Renshaw analyst Ram Selvaraju weighed in today with a few insights on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), ahead of the the upcoming Phase 3 …
Analyst Ram Selvaraju from Rodman & Renshaw believes that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has upcoming developments that will help revive the company after …
Analysts weigh in on drug makers Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Synergy Pharmaceuticals Inc (NASDAQ:SGYP), and EXACT Sciences Corporation (NASDAQ:EXAS). While Valeant just hosted an investor …
Considerable strength remains visible among biotechnology stocks, as reflected by the one percent gain being posted by the iShares NASDAQ Biotechnology Index in pre-market …
As Valeant Pharmaceuticals Intl Inc (NYSE:VRX) continues to deal with bad press, one analyst believes there is nothing to worry about. On the …
U.S.
Healthcare analysts from Mizuho and Rodman and Renshow explain their views on recent announcements made by Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Synergy …
Analysts are bullish on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) as Valeant’s CEO has returned from sick leave and …
